Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a ...
MPR

Sonelokimab Receives FDA Fast Track Status for Palmoplantar Pustulosis

Sonelokimab receives FDA Fast Track status for palmoplantar pustulosis following phase 2 trial data showing significant symptom reduction.
STAT

Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment

Trump administration officials vetoed the FDA's plan to fast-track the review of a psychedelic treatment for severe ...
Targeted Oncology

Pelareorep Earns FDA Fast Track for Second-Line KRAS-Mutant Metastatic CRC

The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...
CURE

Pelareorep Receives FDA Fast Track Status for KRAS-Mutant Colorectal Cancer

The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers.